“The distribution agreement provides medical diagnostics company, Apacor Limited with the right to sell an immunoassay version of PromarkerD in England, Wales and Scotland. Incredibly, Proteomics says some 10 per cent of the UK’s National Health Service annual budget, equating to more than £10 billion, is spent on the treatment of diabetes.“
“Proteomics’ commercialisation push for PromarkerD appears to be gathering steam with a UK distribution agreement now firmly in place. Pundits will likely be keeping a keen eye on the Perth-based company as it advances discussions with other key parties as it aims to bring its predictive kidney test to other major markets around the world.“
Article: Proteomics enters lucrative UK market for kidney test
